{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:20:40Z","timestamp":1782969640176,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.tjog.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T15:54:10Z","timestamp":1741103650000},"page":"230-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Menopause part I: Vasomotor symptoms (I)"],"prefix":"10.1016","volume":"64","author":[{"given":"Peng-Hui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ling","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2025.01.001_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2025.01.001_bib2","article-title":"Menopause decoded: what's happening and how to manage it","volume":"15","author":"Strelow","year":"2024","journal-title":"J\u00a0Prim Care Community Health"},{"key":"10.1016\/j.tjog.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejogrb.2024.09.013","article-title":"Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape","volume":"302","author":"Pertynska-Marczewska","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.tjog.2025.01.001_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tjog.2024.07.014","article-title":"Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer","volume":"63","author":"Chang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tjog.2024.08.001","article-title":"Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.tjog.2024.09.005","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib8","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tjog.2024.09.006","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): anti-HER2\/neu","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/03630242.2024.2392136","article-title":"Epidemiology and clinical outcomes of vasomotor symptoms among perimenopausal women and women aged 65 years or older in the US: a systematic review","volume":"64","author":"Gibson","year":"2024","journal-title":"Women Health"},{"key":"10.1016\/j.tjog.2025.01.001_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/09513590.2022.2162035","article-title":"Vasomotor symptoms and management of women undergoing treatment for breast cancer: literature review with focus on the therapeutic potential of cytoplasmic pollen extract","volume":"39","author":"Lello","year":"2023","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.tjog.2025.01.001_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/GME.0000000000002451","article-title":"Prevalence and impact of vasomotor symptoms due to menopause among women in Canada: a subgroup analysis from an international cross-sectional survey of Women with Vasomotor Symptoms Associated with Menopause (WARM Study)","volume":"32","author":"Yuksel","year":"2025","journal-title":"Menopause"},{"key":"10.1016\/j.tjog.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause Transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.tjog.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13697137.2023.2256658","article-title":"Global view of vasomotor symptoms and sleep disturbance in menopause: a systematic review","volume":"26","author":"Kingsberg","year":"2023","journal-title":"Climacteric"},{"key":"10.1016\/j.tjog.2025.01.001_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13697130500515776","article-title":"Mid-age health in women from the Indian subcontinent (MAHWIS): general health and the experience of menopause in women","volume":"9","author":"Gupta","year":"2006","journal-title":"Climacteric"},{"key":"10.1016\/j.tjog.2025.01.001_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.maturitas.2016.03.017","article-title":"Hot flushes and reproductive hormone levels during the menopausal transition","volume":"89","author":"Dhanoya","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.tjog.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/GME.0b013e3182952228","article-title":"Premenopausal vasomotor symptoms in an ethnically diverse population","volume":"21","author":"Reed","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.tjog.2025.01.001_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2024.108087","article-title":"Neuroendocrine mechanisms of mood disorders during menopause transition: a narrative review and future perspectives","volume":"188","author":"Fidecicchi","year":"2024","journal-title":"Maturitas"},{"key":"10.1016\/j.tjog.2025.01.001_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/d41586-023-01474-3","article-title":"How menopause reshapes the brain","volume":"617","author":"Ledford","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tjog.2025.01.001_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1507\/endocrj.EJ24-0006","article-title":"The role of KNDy neurons in human reproductive health","volume":"71","author":"Oride","year":"2024","journal-title":"Endocr J"},{"key":"10.1016\/j.tjog.2025.01.001_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-0043-1769734","article-title":"Understanding why homeopathic medicines are used for menopause: searching for insights into neuroendocrine features","volume":"113","author":"Mac\u00edas-Cort\u00e9s","year":"2024","journal-title":"Homeopathy"},{"key":"10.1016\/j.tjog.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/endrev\/bnad023","article-title":"The emerging therapeutic potential of kisspeptin and neurokinin B","volume":"45","author":"Patel","year":"2024","journal-title":"Endocr Rev"},{"key":"10.1016\/j.tjog.2025.01.001_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2024.108096","article-title":"Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: findings from the REALISE study","volume":"189","author":"Kingsberg","year":"2024","journal-title":"Maturitas"},{"key":"10.1016\/j.tjog.2025.01.001_bib23","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.tjog.2024.09.004","article-title":"Breakthroughs in women's health for treating vasomotor symptoms","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2025.01.001_bib25","series-title":"StatPearls [internet]. Treasure island (FL)","article-title":"Hormone replacement therapy","author":"Harper-Harrison","year":"2024"},{"key":"10.1016\/j.tjog.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.mayocp.2024.03.028","article-title":"Management of the vasomotor symptoms of menopause: twofers in your clinical toolbox","volume":"99","author":"Kling","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tjog.2025.01.001_bib27","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1001\/jama.2024.6542","article-title":"The women's health initiative randomized trials and clinical practice: a review","volume":"331","author":"Manson","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2025.01.001_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fgwh.2024.1397123","article-title":"Hormone replacement therapy perspectives","volume":"5","author":"Kissinger","year":"2024","journal-title":"Front Glob Womens Health"},{"key":"10.1016\/j.tjog.2025.01.001_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101819","article-title":"Non-oestrogen-based and complementary therapies for menopause","volume":"38","author":"Al Wattar","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.tjog.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3949\/ccjm.91a.23067","article-title":"Nonhormone therapies for vasomotor symptom management","volume":"91","author":"Iyer","year":"2024","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.tjog.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.tjog.2023.07.013","article-title":"Association between traditional Chinese medicine body constitution deviation and chronic pelvic pain: a cross-sectional study","volume":"62","author":"Chen","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib32","article-title":"Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause","volume":"17","author":"Conklin","year":"2023","journal-title":"Ther Adv Reprod Health"},{"key":"10.1016\/j.tjog.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"19846","DOI":"10.1073\/pnas.1211517109","article-title":"Role for kisspeptin\/neurokinin B\/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature","volume":"109","author":"Mittelman-Smith","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tjog.2025.01.001_bib34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","article-title":"Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes","volume":"34","author":"Rance","year":"2013","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.tjog.2025.01.001_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/GME.0000000000000763","article-title":"Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women's Health Initiative Study","volume":"24","author":"Crandall","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.tjog.2025.01.001_bib36","unstructured":"PAVINETANT, 3U471ZVC5K. US Department of Health & Human Services. National Institutes of Health, National Center for Advancing Translational Sciences, Inxight Drugs. https:\/\/drugs.ncats.io\/drug\/3U471ZVC5K [Accessed on 30 December 2024]."},{"key":"10.1016\/j.tjog.2025.01.001_bib37","unstructured":"ELISMETREP, MT-8554. US Department of Health & Human Services. National Institutes of Health, National Center for Advancing Translational Sciences, Inxight Drugs. https:\/\/drugs.ncats.io\/substances?q=22MT-855422&facet=Substance20Form2FPrincipal20Form [Accessed on 30 December 2024]."},{"key":"10.1016\/j.tjog.2025.01.001_bib38","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/S0140-6736(22)01977-8","article-title":"Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"400","author":"Vrselja","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2025.01.001_bib39","article-title":"Fezolinetant and elinzanetant therapy for menopausal women experiencing vasomotor symptoms: a systematic review and meta-analysis","volume":"2","author":"Menegaz de Almeida","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib40","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials","volume":"332","author":"Pinkerton","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2025.01.001_bib41","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2025.01.001_bib42","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.tjog.2025.01.001_bib43","first-page":"737","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib44","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s12325-024-02849-2","article-title":"Validation and application of thresholds to define meaningful change in vasomotor symptoms frequency: analysis of pooled SKYLIGHT 1 and 2 data","volume":"41","author":"Morga","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.tjog.2025.01.001_bib45","article-title":"Safety of fezolinetant for treatment of moderate to severe vasomotor symptoms due to menopause: pooled analysis of three randomized phase 3 studies","volume":"30","author":"Kagan","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.tjog.2025.01.001_bib46","article-title":"Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial","volume":"387","author":"Schaudig","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.tjog.2025.01.001_bib47","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.tjog.2024.09.001","article-title":"Minimally invasive surgery for endometrial cancer: the better choice?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.01.001_bib48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JCMA.0000000000001069","article-title":"Minimally invasive approach is preferred for clinical stage 1 endometrioid-type endometrial cancer","volume":"87","author":"Wang","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.01.001_bib49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/JCMA.0000000000001055","article-title":"Clinical outcomes and patient-reported outcomes after oncoplastic breast surgery in breast cancer patients: a matched cohort study","volume":"87","author":"Chou","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.01.001_bib50","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/JCMA.0000000000001163","article-title":"Increased risk of major adverse cardiovascular events in young and middle-aged adults with obesity receiving Chinese herbal medicine: a nationwide cohort study","volume":"87","author":"Yang","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.01.001_bib51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/JCMA.0000000000001026","article-title":"Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: a systemic review and network meta-analysis","volume":"87","author":"Chen","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.01.001_bib52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/JCMA.0000000000001037","article-title":"The effect of radiotherapy on patients with pathological stage IIB breast cancer after breast-conserving surgery or mastectomy: a cohort study","volume":"87","author":"Pan","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.01.001_bib53","article-title":"Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I)","volume":"52","author":"Ruan","year":"2024","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.tjog.2025.01.001_bib54","article-title":"Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial","volume":"52","author":"Yu","year":"2024","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.tjog.2025.01.001_bib55","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/13697137.2024.2356854","article-title":"Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan","volume":"27","author":"Takamatsu","year":"2024","journal-title":"Climacteric"},{"key":"10.1016\/j.tjog.2025.01.001_bib56","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/ijgo.15467","article-title":"Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials","volume":"166","author":"Akhtar","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.01.001_bib57","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036592","article-title":"Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: a systematic review and meta-analysis","volume":"102","author":"Rahman","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.tjog.2025.01.001_bib58","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/GME.0000000000002281","article-title":"Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause","volume":"31","author":"Morga","year":"2024","journal-title":"Menopause"},{"key":"10.1016\/j.tjog.2025.01.001_bib59","unstructured":"What you need to know about fezolinetant \u2013 The new menopause medication without hormones. https:\/\/mcpress.mayoclinic.org\/menopause\/what-you-need-to-know-about-fezolinetant-the-new-menopause-medication-without-hormones\/[Accessed on 30 December 2024]."},{"key":"10.1016\/j.tjog.2025.01.001_bib60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.46747\/cfp.7004245","article-title":"Top studies of 2023 relevant to primary care: from the PEER team","volume":"70","author":"Thomas","year":"2024","journal-title":"Can Fam Physician"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T15:39:34Z","timestamp":1741621174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455925000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1028455925000191"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2025.01.001","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menopause part I: Vasomotor symptoms (I)","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}